St Jude Medical has launched the Trifecta valve with Glide Technology (GT) in the USA. The valve is designed for the treatment of patients diagnosed with unhealthy, damaged or malfunctioning aortic heart valves.
The tissue valve is intended to allow for an enhanced valve delivery method to ease implantation in challenging anatomies and during minimally invasive surgical approaches.
“The new tissue valve offers enhancements that will only make the implantation process smoother, providing a solution to patients with even the most challenging of cases,” says Trey Pluscht, a cardiothoracic surgeon at Cardio-Thoracic and Vascular Surgical Associates, Alabama, USA. “I welcome the opportunity to offer patients the life-changing benefits we’ve come to expect from this family of valves.”
According to a company release, the Trifecta GT tissue valve has improved upon the original, and provides physicians a tissue valve option that is easier to implant while retaining its optimal hemodynamic performance.
Engineered to reduce wear and deterioration over time, the Trifecta GT stented tissue valve is designed to offer improved tissue-to-tissue contact when the leaflets open and close. Additionally, the valve is treated with the St Jude Medical Linx AC treatment, an anticalcification treatment designed to reduce tissue mineralisation. The valve’s fatigue-resistant titanium stent should provide a supportive frame within a patient’s heart for added durability.
The Trifecta GT tissue valve received FDA approval in April 2016. The tissue valve is also CE mark approved.